Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
Marie Christine Wulff Westergaard, Rikke Andersen, Chloé Chong, Julie Westerlin Kjeldsen, Magnus Pedersen, Christina Friese, Thomas Hasselager, Henrik Lajer, George Coukos, Michal Bassani-Sternberg, Marco Donia, Inge Marie Svane, Marie Christine Wulff Westergaard, Rikke Andersen, Chloé Chong, Julie Westerlin Kjeldsen, Magnus Pedersen, Christina Friese, Thomas Hasselager, Henrik Lajer, George Coukos, Michal Bassani-Sternberg, Marco Donia, Inge Marie Svane
Abstract
Background: Solid malignancies are frequently infiltrated with T cells. The success of adoptive cell transfer (ACT) with expanded tumour-infiltrating lymphocytes (TILs) in melanoma warrants its testing in other cancer types. In this preclinical study, we investigated whether clinical-grade TILs could be manufactured from ovarian cancer (OC) tumour specimens.
Methods: Thirty-four tumour specimens were obtained from 33 individual patients with OC. TILs were analysed for phenotype, antigen specificity and functionality.
Results: Minimally expanded TILs (Young TILs) were successfully established from all patients. Young TILs contained a high frequency of CD3+ cells with a variable CD4/CD8 ratio. TILs could be expanded to clinical numbers. Importantly, recognition of autologous tumour cells was demonstrated in TILs in >50% of the patients. We confirmed with mass spectrometry the presentation of multiple tumour antigens, including peptides derived from the cancer-testis antigen GAGE, which could be recognised by antigen-specific TILs. Antigen-specific TILs could be isolated and further expanded in vitro.
Conclusion: These findings support the hypothesis that patients with OC can benefit from ACT with TILs and led to the initiation of a pilot clinical trial at our institution .
Trial registration: clinicaltrials.gov: NCT02482090.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Gooden MJM, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer. 2011;105:93–103. doi: 10.1038/bjc.2011.189.
- Adams SF, et al. Intraepithelial T cells and tumour proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 2009;115:2891–2902. doi: 10.1002/cncr.24317.
- Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003;348:203–213. doi: 10.1056/NEJMoa020177.
- Sato E, et al. Intraepithelial CD8+tumour-infiltrating lymphocytes and a hiThe Danish National Committee on Health Research Ethics approved the scientific use of the patient material (protocol number H-2–2014–055).gh CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA. 2005;102:18538–18543. doi: 10.1073/pnas.0509182102.
- Kvistborg P, van Buuren MM, Schumacher TN. Human cancer regression antigens. Curr. Opin. Immunol. 2013;25:284–290. doi: 10.1016/j.coi.2013.03.005.
- Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. doi: 10.1126/science.aaa4971.
- Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348:62–68. doi: 10.1126/science.aaa4967.
- Wick Da, et al. Surveillance of the tumour mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 2014;20:1125–1134. doi: 10.1158/1078-0432.CCR-13-2147.
- Ye Q, et al. CD137 accurately identifies and enriches for naturally occurring tumour-reactive T cells in tumour. Clin. Cancer Res. 2014;20:44–55. doi: 10.1158/1078-0432.CCR-13-0945.
- Attig S, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 2009;69:8412–8419. doi: 10.1158/0008-5472.CAN-09-0852.
- Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi: 10.1038/nature12477.
- Coukos G, Tanyi J, Kandalaft LE. Opportunities in immunotherapy of ovarian cancer. Ann. Oncol. 2016;27:i11–i15. doi: 10.1093/annonc/mdw084.
- Armstrong DK, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2016;354:34–43. doi: 10.1056/NEJMoa052985.
- . (2016).
- Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012;188:2148–2149.
- Hamanishi J, et al. Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 2015;33:4015–4022. doi: 10.1200/JCO.2015.62.3397.
- Varga A., et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J. Clin. Oncol. 33(Suppl.): abstr 5510 (2015).
- Disis ML, et al. 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: a phase Ib trial reporting safety and clinical activity. Eur. J. Cancer. 2015;51:S546–S547. doi: 10.1016/S0959-8049(16)31515-5.
- Donia M, et al. Characterization and comparison of ‘standard’ and ‘young’ tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand. J. Immunol. 2011;75:157–167. doi: 10.1111/j.1365-3083.2011.02640.x.
- Donia M, et al. Aberrant expression of MHC Class II in melanoma attracts inflammatory tumour specific CD4+T cells which dampen CD8+T cell antitumor reactivity. Cancer Res. 2015;75:3747–3760. doi: 10.1158/0008-5472.CAN-14-2956.
- Peper JK, et al. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J. Immunol. Methods. 2014;405:192–198. doi: 10.1016/j.jim.2014.01.012.
- Chong C, et al. High-throughput and sensitive immunopeptidomics platform reveals profound interferonγ-mediated remodeling of the human leukocyte antigen (HLA) ligandome. Mol. Cell. Proteomics. 2018;17:533–548. doi: 10.1074/mcp.TIR117.000383.
- Toebes M, et al. Design and use of conditional MHC class I ligands. Nat. Med. 2006;12:246–251. doi: 10.1038/nm1360.
- Andersen R, et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumour-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 2016;22:3734–3745. doi: 10.1158/1078-0432.CCR-15-1879.
- Junker N, et al. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy. 2011;13:822–834. doi: 10.3109/14653249.2011.563291.
- Andersen R, et al. T-cell responses in the microenvironment of primary renal cell carcinoma-implications for adoptive cell therapy. Cancer Immunol. Res. 2018;6:222–235. doi: 10.1158/2326-6066.CIR-17-0467.
- Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 2004;22:745–763. doi: 10.1146/annurev.immunol.22.012703.104702.
- Donia M, Larsen SM, Met O, Svane IM. Simplified protocol for clinical-grade tumour-infiltrating lymphocyte manufacturing with use of the wave bioreactor. Cytotherapy. 2014;0:1–4.
- Besser MJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumour infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2010;16:2646–2655. doi: 10.1158/1078-0432.CCR-10-0041.
- Lo CS, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumour-infiltrating lymphocyte response with distinct implications for immunotherapy. Am. Assoc. Cancer Res. 2017;23:925–934.
- Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumour-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003;26:332–342. doi: 10.1097/00002371-200307000-00005.
- Itzhaki O, et al. Establishment and large-scale expansion of minimally cultured ‘young’ tumour infiltrating lymphocytes for adoptive transfer therapy. J. Immunother. 2011;34:212–220. doi: 10.1097/CJI.0b013e318209c94c.
- Turcotte S, et al. Tumor-reactive cd8+ tcells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin. Cancer Res. 2014;20:331–343. doi: 10.1158/1078-0432.CCR-13-1736.
- Markel GAL, et al. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma. Anticancer Res. 2009;154:145–154.
- Baldan V, Griffiths R, Hawkins RE, Gilham DE. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma. Br. J. Cancer. 2015;112:1510–1518. doi: 10.1038/bjc.2015.96.
- Owens GL, et al. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells. Cancer Immunol. Immunother. 2018;67:1519–1531. doi: 10.1007/s00262-018-2211-3.
- Linnemann C, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+T cells in human melanoma. Nat. Med. 2014;21:1–7.
- Friedman KM, et al. Tumor-specific CD4+melanoma tumour-infiltrating lymphocytes. J. Immunother. 2012;35:400–408. doi: 10.1097/CJI.0b013e31825898c5.
- Backer ODe, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis characterization of the GAGE genes that are expressed in various human cancers and in normal testis 1. Cancer Res. 1999;59:3157–3165.
- Bobisse B, et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8+T cells in immunotherapy-naive ovarian cancer. Nat. Commun. 2018;9:1–10. doi: 10.1038/s41467-018-03301-0.
- Martin SD, et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS ONE. 2016;11:1–22.
- Bassani-Sternberg M, Coukos G. Mass spectrometry-based antigen discovery for cancer immunotherapy. Curr. Opin. Immunol. 2016;41:9–17. doi: 10.1016/j.coi.2016.04.005.
- Kelderman S, et al. Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy. Eur. J. Immunol. 2016;46:1351–1360. doi: 10.1002/eji.201545849.
Source: PubMed